About the Company
tracon pharmaceuticals, inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for cancer and wet age-related macular degeneration (amd). its lead clinical stage products include envafolimab (kn035), an investigational pd-l1 single-domain antibody for the treatment of soft tissue sarcoma. the company's clinical stage products also include de-122, which is in randomized phase iia study for the treatment of wet amd; trc102, which is a small molecule that is in phase ii clinical trial for the treatment of mesothelioma, phase i clinical trial to treat solid tumors, phase i/ii to treat solid tumors and lymphomas, and phase i trial to treat lung cancer; trc253, a small molecule, which is in a phase ii clinical trial for the treatment of metastatic castration-resistant prostate cancer; and tj004309, a cd73 antibody that is in phase i clinical development for the treatment of solid tumors. it has collaboration and license agreements w
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $TCON News
TRACON Pharmaceuticals Inc TCON
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...
TRACON Pharmaceuticals Inc T051
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
TRACON Pharmaceuticals Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update
Research and development expenses for the fourth quarter of 2023 were $1.5 million, compared to $3.9 million for the fourth quarter of 2022. The decrease was primarily related to enrollment into only ...
Buy Rating for TRACON Pharmaceuticals on Strong Financials and Promising Clinical Trials
Maxim Group analyst Jason McCarthy maintained a Buy rating on TRACON Pharmaceuticals (TCON – Research Report) yesterday and set a price ...
TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) Q4 2023 Earnings Call Transcript
Q4 2023 Earnings Call March 5, 2024 TRACON Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is $0.01, ...
TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) Q4 2023 Earnings Call Transcript
TRACON Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is $0.01, expectations were $-0.03. TCON isn’t one of the 30 most popular stocks among hedge funds at the end of the third ...
TRACON Pharmaceuticals Inc.
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
TRACON Pharmaceuticals, Inc. (TCON) Q4 2023 Earnings Call Transcript
Good day, ladies and gentlemen, and welcome to the TRACON Pharmaceuticals Fourth Quarter and Year-End 2023 Earnings Conference Call. [Operator Instructions] During today's call, we will be making ...
TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) Q4 2023 Earnings Call Transcript
And to make clear what that potentially can mean to TRACON, if it’s a Phase I study and, for example, we can do a 30-patient Phase I study at $3 million and we know a CRO will charge typically $ ...
Loading the latest forecasts...